
The 20th Annual BIO International Convention: We'll See You in Chicago

2013-04-03

The 20th annual [BIO International Convention](#)—the largest global event for the biotechnology industry, featuring keynote addresses and sessions led by key policymakers, scientists, CEOs and celebrities—will be taking place from April 22-25, 2013 in Chicago, Illinois. WilmerHale is pleased to not only be a sponsor, but to have an active role in presentations throughout the pre-convention and convention, which is expected to welcome thousands of industry leaders from across the globe.

The firm will present three discussion panels at BIO, as well as a session during the pre-convention:

Saturday, April 20 from 8:30 a.m.–12:30 p.m.

Partner Steve Barrett will present a session on “Contract Basics” as part of the [BIO-LES Business Development Basics Course](#). This three-day course has been offered as a joint collaboration between the Biotechnology Industry Organization and the Licensing Executives Society since 2003. It provides an intensive and comprehensive educational foundation on the core skills needed to be a successful licensing executive in the life sciences industry.

Monday, April 22 from 10:15–11:30 a.m.

Partner Belinda Juran will moderate a panel session on the Finance track, “[Venture Philanthropy: For-Profit Biotechs can Benefit from Non-Profit Investments](#).” This session will bring together representatives from nonprofit organizations as well as the for-profit biotechs that have been funded, in whole or in part, by such organizations, to discuss the best ways for funders and recipients to align their interests.

Tuesday, April 23 from 9–10:15 a.m.

Special Counsel Cynthia Mazareas will moderate a discussion panel on the Business Development track, “[Bridging the Productivity Gap: Current Big Pharma Strategies for Accessing Early-Stage Innovation](#).” Her panel will address efforts being made by big pharma to accelerate its involvement and investment in early-stage innovation through relationships with VCs and startups, focusing on the objectives of these arrangements; the major challenges facing pharma today that are driving these efforts; and the potential implications, benefits and risks associated with these new strategies.

Tuesday, April 23 from 10:30–11:30 a.m.

Partner Mark Fleming will moderate a discussion panel on the Biotech Patenting and Tech Transfer track, “[Myriad, Mayo, and Beyond: Developments in the Law of Patentable Subject Matter](#).” This session will address the latest developments regarding the patenting of isolated DNA molecules in Association for *Molecular Pathology v. USPTO*, commonly known as the Myriad Genetics case; the continuing aftermath of the US Supreme Court’s decision in *Mayo Collaborative Services v. Prometheus Labs, Inc.*; and

related developments in the courts and Congress that could affect the biotechnology industry. Panelists include Partner Seth Waxman and Senior Counsel Arthur Gajarsa.

Representatives from the firm will be at booth #3450 in the sponsor section of the exhibit hall.